XORTX Therapeutics shares surge 11.60% premarket after announcing substitute director nominees for board.

XORTX Therapeutics Inc. surged 11.6% in premarket trading following the announcement of substitute director nominees for its upcoming annual and special meeting. The company disclosed that George Scorsis, Richard Grieve, and Mika Grasso would replace outgoing director Krysta, signaling a strategic shift in board leadership. This change is likely perceived as a positive development by investors, as it may align with efforts to strengthen governance or diversify expertise. While prior-day closing data showed a 6.45% gain, the premarket rally appears driven by the fresh board restructuring news, which underscores potential operational or strategic realignments. Other recent updates, including unrelated JavaScript-related content, lack direct relevance to the stock’s movement.